Medical Oncology

The Medical Oncology department provides quality diagnosis, treatment, and care for patients with cancer.

Medical Oncology Staff List

Paul F. Engstrom, MD
Acting Director, Medical Oncology

David Eli Adelberg, MD
Attending Physician, Medical Oncology

Igor Astsaturov MD, PhD

Marijo Bilusic, MD, PhD, Attending Physician, Medical Oncology

Hossein Borghaei, DO, Chief, Thoracic Medical Oncology

Barbara Burtness, MD, Chief, Head and Neck Medical Oncology, Medical Oncology

Jonathan D. Cheng, MD

Adam D. Cohen, MD

Steven J. Cohen MD,
Chief, Gastrointestinal Medical Oncology, Medical Oncology

Crystal S. Denlinger, MD

Efrat Dotan, MD

Scot W. Ebbinghaus, MD, Attending Physician, Medical Oncology

Omotayo Fasan, MBBS, MRCP (UK),
Attending Physician, Bone Marrow Transplant

Lori Goldstein, MD

Gary R. Hudes, MD

Michael J. Kane, MD, FACP

Thomas R. Klumpp, MD, FACP

Patricia L. Kropf, MD

Gregory Michael Lubiniecki, MD

Kenneth F. Mangan, MD, FACP,
Director, Bone Marrow Transplant Program

Lainie P. Martin, MD

Mary Ellen Martin, MD

Ranee Mehra, MD

Michael M. Millenson, MD, Director, Hematology Service, Medical Oncology

Tara Morrison, MD, FRCP (C)

Sujana Movva, MD

Anthony J. Olszanski, MD, RPh,
Director, Clinical Pharmacology

Elizabeth Plimack, MD, MS

Michael V Seiden, MD, PhD

Manish Sharma, MD,
Assistant Director, Bone Marrow Transplant Program, Medical Oncology

Joseph Treat, MD

Margaret von Mehren, MD ,
Director, Sarcoma Program

Yu-Ning Wong, MD, MSCE

 

Pain and Palliative Care

Michael H Levy, MD, PhD
Vice Chair, Medical Oncology

Marcin Chwistek, MD
Attending Physician, Medical Oncology

Advanced Practice Clinicians

Colleen H Erb, MSN, CRNP, ACNP-BC
Nurse Practitioner, Medical Oncology/Hematology
Kristen Kreamer, CRNP, MSN, AOCN, APRN-BC
Ann Pellegrino, OCN, MSN, ANP-BC
Susan Roethke, CRNP, MSN, AOCN, ANP-BC
Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Eric Tetzlaff, PA-C, Physician Assistant, Medical Oncology
Kathryn Tumelty, MSN, AOCNP

 

 

 

 

Traditional chemotherapy and new clinical trials provide our Medical Oncologists with access to a tremendous range of new anticancer treatments, including medicines and combinations of medicines.

"Personalized" treatment involves identifying characteristics of individual patients' tumors in order to determine their responsiveness to specific chemotherapy drugs. The ultimate goal of such analysis is to determine which tumors are sensitive to a given drug and equally important, which tumors are resistant to specific drugs.

A similar approach has already benefited the Fox Chase Gastrointestinal Cancer program, where patients with metastatic colorectal cancer are routinely screened for mutations in the K-RAS gene to determine the most effective drug treatment. Fox Chase's Clinical Molecular Genetics Laboratory has been conducting this test since 2007.

This focus on personalized medicine is just another example of Fox Chase's leadership in bringing state-of-the-art research directly to the bedside and delivering expert and compassionate care with the goal of improving patient outcomes.